139 related articles for article (PubMed ID: 37866885)
1. Sulfasalazine, a potent cystine-glutamate transporter inhibitor, enhances osteogenic differentiation of canine adipose-derived stem cells.
Itoh H; Tani K; Sunahara H; Nemoto Y; Nakaichi M; Horikirizono H; Itamoto K
J Vet Med Sci; 2023 Nov; 85(11):1237-1244. PubMed ID: 37866885
[TBL] [Abstract][Full Text] [Related]
2. Cystine transporter expression is a marker to identify a subpopulation of canine adipose-derived stem cells.
Itoh H; Nishikawa S; Tani K; Sunahara H; Nakaichi M; Iseri T; Taura Y; Itamoto K
J Vet Med Sci; 2020 Jun; 82(6):713-720. PubMed ID: 32269196
[TBL] [Abstract][Full Text] [Related]
3. Glutaminolysis-related genes determine sensitivity to xCT-targeted therapy in head and neck squamous cell carcinoma.
Okazaki S; Umene K; Yamasaki J; Suina K; Otsuki Y; Yoshikawa M; Minami Y; Masuko T; Kawaguchi S; Nakayama H; Banno K; Aoki D; Saya H; Nagano O
Cancer Sci; 2019 Nov; 110(11):3453-3463. PubMed ID: 31444923
[TBL] [Abstract][Full Text] [Related]
4. Xc- inhibitor sulfasalazine sensitizes colorectal cancer to cisplatin by a GSH-dependent mechanism.
Ma MZ; Chen G; Wang P; Lu WH; Zhu CF; Song M; Yang J; Wen S; Xu RH; Hu Y; Huang P
Cancer Lett; 2015 Nov; 368(1):88-96. PubMed ID: 26254540
[TBL] [Abstract][Full Text] [Related]
5. Dose-escalation study for the targeting of CD44v
Shitara K; Doi T; Nagano O; Imamura CK; Ozeki T; Ishii Y; Tsuchihashi K; Takahashi S; Nakajima TE; Hironaka S; Fukutani M; Hasegawa H; Nomura S; Sato A; Einaga Y; Kuwata T; Saya H; Ohtsu A
Gastric Cancer; 2017 Mar; 20(2):341-349. PubMed ID: 27055559
[TBL] [Abstract][Full Text] [Related]
6. Kinetic analysis of cystine uptake and inhibition pattern of sulfasalazine in A549 cells.
Okamoto K; Saito Y; Ueda H; Narumi K; Furugen A; Kobayashi M
Biopharm Drug Dispos; 2021 Sep; 42(8):389-392. PubMed ID: 34287957
[TBL] [Abstract][Full Text] [Related]
7. Sulfasalazine, an inhibitor of the cystine-glutamate antiporter, reduces DNA damage repair and enhances radiosensitivity in murine B16F10 melanoma.
Nagane M; Kanai E; Shibata Y; Shimizu T; Yoshioka C; Maruo T; Yamashita T
PLoS One; 2018; 13(4):e0195151. PubMed ID: 29649284
[TBL] [Abstract][Full Text] [Related]
8. Potential of sulfasalazine as a therapeutic sensitizer for CD44 splice variant 9-positive urogenital cancer.
Takayama T; Kubo T; Morikawa A; Morita T; Nagano O; Saya H
Med Oncol; 2016 May; 33(5):45. PubMed ID: 27044355
[TBL] [Abstract][Full Text] [Related]
9. Cystine-glutamate antiporter xCT as a therapeutic target for cancer.
Liu L; Liu R; Liu Y; Li G; Chen Q; Liu X; Ma S
Cell Biochem Funct; 2021 Mar; 39(2):174-179. PubMed ID: 32749001
[TBL] [Abstract][Full Text] [Related]
10. Convection-enhanced delivery of sulfasalazine prolongs survival in a glioma stem cell brain tumor model.
Haryu S; Saito R; Jia W; Shoji T; Mano Y; Sato A; Kanamori M; Sonoda Y; Sampetrean O; Saya H; Tominaga T
J Neurooncol; 2018 Jan; 136(1):23-31. PubMed ID: 28929335
[TBL] [Abstract][Full Text] [Related]
11. The xc- cystine/glutamate antiporter as a potential therapeutic target for small-cell lung cancer: use of sulfasalazine.
Guan J; Lo M; Dockery P; Mahon S; Karp CM; Buckley AR; Lam S; Gout PW; Wang YZ
Cancer Chemother Pharmacol; 2009 Aug; 64(3):463-72. PubMed ID: 19104813
[TBL] [Abstract][Full Text] [Related]
12. Vasodilator oxyfedrine inhibits aldehyde metabolism and thereby sensitizes cancer cells to xCT-targeted therapy.
Otsuki Y; Yamasaki J; Suina K; Okazaki S; Koike N; Saya H; Nagano O
Cancer Sci; 2020 Jan; 111(1):127-136. PubMed ID: 31692172
[TBL] [Abstract][Full Text] [Related]
13. Burn injury induces the expression of cystine/glutamate transporter (x(c)(-)) in mouse T cells.
D'Elia M; Patenaude J; Dupras C; Bernier J
Immunol Lett; 2009 Aug; 125(2):137-44. PubMed ID: 19576933
[TBL] [Abstract][Full Text] [Related]
14. Roles of intracellular and extracellular ROS formation in apoptosis induced by cold atmospheric helium plasma and X-irradiation in the presence of sulfasalazine.
Moniruzzaman R; Rehman MU; Zhao QL; Jawaid P; Mitsuhashi Y; Imaue S; Fujiwara K; Ogawa R; Tomihara K; Saitoh JI; Noguchi K; Kondo T; Noguchi M
Free Radic Biol Med; 2018 Dec; 129():537-547. PubMed ID: 30355525
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of SLC7A11 by Sulfasalazine Enhances Osteogenic Differentiation of Mesenchymal Stem Cells by Modulating BMP2/4 Expression and Suppresses Bone Loss in Ovariectomized Mice.
Jin C; Zhang P; Zhang M; Zhang X; Lv L; Liu H; Liu Y; Zhou Y
J Bone Miner Res; 2017 Mar; 32(3):508-521. PubMed ID: 27696501
[TBL] [Abstract][Full Text] [Related]
16. High expression of CD44v9 and xCT in chemoresistant hepatocellular carcinoma: Potential targets by sulfasalazine.
Wada F; Koga H; Akiba J; Niizeki T; Iwamoto H; Ikezono Y; Nakamura T; Abe M; Masuda A; Sakaue T; Tanaka T; Kakuma T; Yano H; Torimura T
Cancer Sci; 2018 Sep; 109(9):2801-2810. PubMed ID: 29981246
[TBL] [Abstract][Full Text] [Related]
17. Impact of the glutathione synthesis pathway on sulfasalazine-treated endometrial cancer.
Sendo K; Seino M; Ohta T; Nagase S
Oncotarget; 2022; 13():224-236. PubMed ID: 35106124
[TBL] [Abstract][Full Text] [Related]
18. Sulfasalazine attenuates ACL transection and medial menisectomy-induced cartilage destruction by inhibition of cystine/glutamate antiporter.
Tsai WY; Tsai RY; Liu CC; Wu JL; Wong CS
J Orthop Res; 2016 Apr; 34(4):650-7. PubMed ID: 26466556
[TBL] [Abstract][Full Text] [Related]
19. The role of system Xc
Dang DK; Shin EJ; Tran HQ; Kim DJ; Jeong JH; Jang CG; Nah SY; Sato H; Nabeshima T; Yoneda Y; Kim HC
Neurochem Int; 2017 Sep; 108():254-265. PubMed ID: 28457879
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of xc⁻ transporter-mediated cystine uptake by sulfasalazine analogs.
Shukla K; Thomas AG; Ferraris DV; Hin N; Sattler R; Alt J; Rojas C; Slusher BS; Tsukamoto T
Bioorg Med Chem Lett; 2011 Oct; 21(20):6184-7. PubMed ID: 21889337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
